Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

被引:130
|
作者
del Alcazar, Carlos Rodrigo Gil [1 ]
Hardebeck, Molly Catherine [1 ]
Mukherjee, Bipasha [1 ]
Tomimatsu, Nozomi [1 ]
Gao, Xiaohuan [1 ]
Yan, Jingsheng [2 ]
Xie, Xian-Jin [2 ]
Bachoo, Robert [3 ]
Li, Li [3 ,4 ]
Habib, Amyn A. [3 ,4 ]
Burma, Sandeep [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA
[4] VA North Texas Hlth Care Syst, Dallas, TX USA
基金
美国国家航空航天局;
关键词
PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; DEPENDENT PROTEIN-KINASE; RAPAMYCIN INHIBITOR; PRECLINICAL EVALUATION; ADJUVANT TEMOZOLOMIDE; DAMAGE RESPONSE; CANCER-CELLS; IN-VIVO; ATM; RADIOTHERAPY;
D O I
10.1158/1078-0432.CCR-13-1607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Inhibitors of the DNA damage response (DDR) have great potential for radiosensitization of numerous cancers, including glioblastomas, which are extremely radio- and chemoresistant brain tumors, Currently, there are no DNA double-strand break (DSB) repair inhibitors that have been successful in treating glioblastoma. Our laboratory previously demonstrated that the dual phosphoinositide 3-kinase/mTOR inhibitor NVP-BEZ235 can potently inhibit the two central DDR kinases, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and ataxia-telangiectasia mutated (ATM), in vitro, Here, we tested whether NVP-BEZ235 could also inhibit ATM and DNA-PKcs in tumors in viva and assessed its potential as a radio- and chemosensitizer in preclinical mouse glioblastoma models. Experimental Design: The radiosensitizing effect of NVP-BEZ235 was tested by following tumor growth in subcutaneous and ortho topic glioblastoma models, Tumors were generated using the radioresistant U87-vIII glioma cell line and GBM9 neurospheres in nude mice. These tumors were then treated with ionizing radiation and/or NVP-BEZ235 and analyzed for DNA-PKcs and ATM activation, DSB repair inhibition, and attenuation of growth. Results: NVP-BEZ235 potently inhibited both DNA-PKcs and ATM kinases and attenuated the repair of ionizing radiation-induced DNA damage in tumors. This resulted in striking tumor radiosensitization, which extended the survival of brain tumor-bearing mice. Notably, tumors displayed a higher DSB-load when compared with normal brain tissue. NVP-BEZ235 also sensitized a subset of subcutaneous tumors to temozolomide, a drug routinely used concurrently with ionizing radiation for the treatment of glioblastoma. Conclusions: These results demonstrate that it may be possible to significantly improve glioblastoma therapy by combining ionizing radiation with potent and bioavailable DNA repair inhibitors such as NVP-BEZ235. (C) 2013 AACR.
引用
收藏
页码:1235 / 1248
页数:14
相关论文
共 50 条
  • [1] Inhibition of DNA repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a novel radiosensitization strategy for glioblastoma
    Del Alcazar, Carlos Gil
    Gillam, Molly
    Tomimatsu, Nozomi
    Gao, Xiaohuan
    Mukherjee, Bipasha
    Burma, Sandeep
    CANCER RESEARCH, 2013, 73 (08)
  • [2] Radiosensitization by the Dual PI3K/mTOR inhibitor NVP-BEZ235
    Cerniglia, George J.
    Karar, Jayashree
    Koumenis, Constantinos
    Maity, Amit
    CANCER RESEARCH, 2012, 72
  • [3] Radiosensitization by the Dual PI3K/mTOR Inhibitor NVP-BEZ235
    Maity, A.
    Cerniglia, G. J.
    Karar, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S84 - S85
  • [4] Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual PI3K/mTOR Inhibitor NVP-BEZ235
    Maity, A.
    Cerniglia, G. J.
    Karar, J.
    Koumenis, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S127 - S127
  • [5] Significant Radiation Sensitization of HNSCC-Cell Lines by the dual PI3K/mTOR/Akt Inhibitor NVP-BEZ235 caused by Inhibition of Double-Strand Break Repair
    Balzer, V
    Arenz, A.
    Preising, S.
    Ziemann, F.
    Klussmann, J-P
    Dikomey, E.
    Engenhart-Cabillic, R.
    Wittig, A.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2016, 192 : 63 - 64
  • [6] Drug irradiation schedule is decisive for radiosensitization by the novel dual PI3K and mTOR inhibitor NVP-BEZ235
    Kuger, S.
    Graus, D.
    Brendtke, R.
    Lutyj, P.
    Soukhoroukov, V
    Flentje, M.
    Djuzenova, C. S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 : 67 - 67
  • [7] Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule
    Kuger, Sebastian
    Graus, Dorothea
    Brendtke, Rico
    Guenther, Nadine
    Katzer, Astrid
    Lutyj, Paul
    Polat, Buelent
    Chatterjee, Manik
    Sukhorukov, Vladimir L.
    Flentje, Michael
    Djuzenova, Cholpon S.
    TRANSLATIONAL ONCOLOGY, 2013, 6 (02): : 169 - U243
  • [8] SYNTHESIS AND PROCESS OPTIMIZATION OF PI3K/MTOR DUAL INHIBITOR NVP-BEZ235
    Xu, T. S.
    Lei, F.
    Tao, H.
    Li, J. Q.
    Zhang, Z. W.
    Wang, L. X.
    Xu, S.
    Zheng, P. W.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 31 - 31
  • [9] Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines
    Masuda, Mitsuhiro
    Shimomura, Manami
    Kobayashi, Ken
    Kojima, Shuji
    Nakatsura, Tetsuya
    ONCOLOGY REPORTS, 2011, 26 (05) : 1273 - 1279
  • [10] The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma
    Bhende, P. M.
    Park, S. I.
    Lim, M. S.
    Dittmer, D. P.
    Damania, B.
    LEUKEMIA, 2010, 24 (10) : 1781 - 1784